MedTrace Logo

Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056

NCT01296711 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2022-04-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the long term safety and tolerability of CDP6038 (olokizumab) treatment in adult subjects with active rheumatoid arthritis who completed study RA0056 (NCT01242488).

Conditions

Interventions

BIOLOGICAL

CDP6038 (olokizumab)

100mg/ml solution for injection 120 mg subcutaneously (sc) every 2 weeks

Sponsors & Collaborators

  • R-Pharm

    collaborator INDUSTRY

  • UCB BIOSCIENCES, Inc.

    lead INDUSTRY

Principal Investigators

  • Mark Genovese, Dr · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-07
Primary Completion
2013-05-01
Completion
2013-08-05

Countries

  • United States
  • Belgium
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01296711 on ClinicalTrials.gov